Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
What Is Novel in the Clinical Management of Pemphigus Vulgaris? Publisher Pubmed



Vafaeian A1 ; Mahmoudi H1 ; Daneshpazhooh M1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Autoimmune Bullous Diseases Research Center, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran

Source: Expert Review of Clinical Pharmacology Published:2024


Abstract

Introduction: Pemphigus, an uncommon autoimmune blistering disorder affecting the skin and mucous membranes, currently with mortality primarily attributed to adverse reactions resulting from treatment protocols. Additionally, the existing treatments exhibit a notable recurrence rate. The high incidence of relapse and the considerable adverse effects associated with treatment underscore the imperative to explore safer and more effective therapeutic approaches. Numerous potential therapeutic targets have demonstrated promising outcomes in trials or preliminary research stages. These encompass anti-CD-20 agents, anti-CD-25 agents, TNF-α inhibition, FAS Ligand Inhibition, FcRn inhibition, BAFF inhibition, Bruton’s tyrosine kinase (BTK) inhibition, CAAR T Cells, JAK inhibition, mTOR inhibition, abatacept, IL-4 inhibition, IL-17 inhibition, IL-6 inhibition, polyclonal Regulatory T Cells, and autologous hematopoietic stem cell transplantation. Areas covered: The most significant studies regarding the impact and efficacy of the mentioned treatments on pemphigus were meticulously curated through a comprehensive search conducted on the PubMed database. Moreover, the investigations of interest cited in these studies were also integrated. Expert opinion: The efficacy and safety profiles of the other treatments under discussion do not exhibit the same level of robustness as anti-CD20 therapy, which is anticipated to endure as a critical element in pemphigus treatment well into the foreseeable future. © 2024 Informa UK Limited, trading as Taylor & Francis Group.
Related Docs
View other Related Docs
1. Pathogenic and Protective Roles of Cytokines in Pemphigus: A Systematic Review, Cytokine (2020)
2. Single-Nucleotide Polymorphisms Associated With Pemphigus Vulgaris: Potent Markers for Better Treatment and Personalized Medicine, International Journal of Immunogenetics (2020)
3. The Possible Role of Interleukin-35 and Its Therapeutic Potential in Pemphigus, International Immunopharmacology (2017)
4. Efficacy and Safety of Bruton's Tyrosine Kinase Inhibitors in the Treatment of Pemphigus: A Comprehensive Literature Review and Future Perspective, Heliyon (2023)
5. Decreased Serum Levels of Interleukin-4 and Interleukin-21 in New Pemphigus Vulgaris Patients, But Not Chronic Patients With Inactive Disease Compared to Healthy Controls, Dermatology Practical and Conceptual (2021)
6. The Dual Nature of Retinoic Acid in Pemphigus and Its Therapeutic Potential: Special Focus on All-Trans Retinoic Acid, International Immunopharmacology (2016)
7. Interleukin 4 Inhibition As a Potential Therapeutic in Pemphigus, Cytokine (2016)
8. Targeting Bruton’S Tyrosine Kinase (Btk) As a Signaling Pathway in Immune-Mediated Diseases: From Molecular Mechanisms to Leading Treatments, Advances in Rheumatology (2024)
Experts (# of related papers)
View all Related Experts
Maryam Daneshpajooh (20)
Hamid Reza Mahmoodi (16)
Other Related Docs
9. Pemphigus Trigger Factors: Special Focus on Pemphigus Vulgaris and Pemphigus Foliaceus, Archives of Dermatological Research (2018)
10. Investigating Expression Pattern of Eight Immune-Related Genes in Pemphigus Patients Compared With the Healthy Controls and After Rituximab Therapy: Potential Roles of Ctla4 and Fcgr3a Genes Expression in Outcomes of Rituximab Therapy, Dermatologic Therapy (2020)
11. Decreased Serum Levels of Interleukin-17, Interleukin-23, Tgf-Β in Pemphigus Vulgaris Patients, and Their Association With Disease Phase, Dermatologic Therapy (2020)
12. Elevated Serum Level of B-Cell Activating Factor (Baff) After Rituximab Therapy in Pemphigus Vulgaris Patients Suggests a Possible Therapeutic Efficacy of B-Cell Depletion Therapies Combined With Anti-Baff Agents, International Journal of Dermatology (2023)
13. The Role of T Helper 17 and Regulatory T Cells in Tumor Microenvironment, Immunopharmacology and Immunotoxicology (2019)
14. Burden of Pemphigus Vulgaris With a Particular Focus on Women: A Review, International Journal of Women's Dermatology (2022)
15. Tofacitinib As the Potent Treatment for Refractory Pemphigus: A Possible Alternative Treatment for Pemphigus, Dermatologic Therapy (2018)
16. Autoimmune Diseases, Clinical Immunology (2022)
17. Rituximab in Practice: Clinical Evaluation of Patients With Pemphigus After Rituximab Administration, Dermatologic Therapy (2021)
18. The Therapeutic Potential of Regulatory T Cells: Challenges and Opportunities, Frontiers in Immunology (2021)
19. Applicability of Glucocorticoid Toxicity Index in Pemphigus: Comparison Between Two Groups of Rituximab-Treated and Rituximab-Naive Patients, Dermatologic Therapy (2022)
20. Cancer Immunology, Encyclopedia of Infection and Immunity (2022)
21. Pemphigus Disease and Area Index: Unmet Needs in the Real-World Management of Pemphigus, Oral Diseases (2023)
22. Cell Therapy in Transplantation: A Comprehensive Review of the Current Applications of Cell Therapy in Transplant Patients With the Focus on Tregs, Car Tregs, and Mesenchymal Stem Cells, International Immunopharmacology (2021)
23. Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
24. Adverse Electrocardiographic Effects of Rituximab Infusion in Pemphigus Patients, Dermatologic Therapy (2020)
25. Intralesional Injection of Biosimilar Rituximab in Recalcitrant Mucocutaneous Lesions of Patients With Pemphigus Vulgaris: A Pilot Study, Dermatologic Therapy (2020)
26. Estimated Cut-Off Values for Pemphigus Severity Classification According to Pemphigus Disease Area Index (Pdai), Autoimmune Bullous Skin Disorder Intensity Score (Absis), and Anti-Desmoglein 1 Autoantibodies, BMC Dermatology (2020)
27. Impact of Rituximab on Igg and Igm Levels in Patients With Autoimmune Bullous Diseases: A Cohort Study, Archives of Dermatological Research (2025)
28. New-Onset or Flare-Up of Bullous Pemphigoid Associated With Covid-19 Vaccines: A Systematic Review of Case Report and Case Series Studies, Frontiers in Medicine (2024)
29. Chimeric Antigen Receptor -T Cell Therapy: Applications and Challenges in Treatment of Allergy and Asthma, Biomedicine and Pharmacotherapy (2020)
30. Current Status and Prospects for the Diagnosis of Pemphigus Vulgaris, Expert Review of Clinical Immunology (2021)
31. Bullous Pemphigoid, Nature Reviews Disease Primers (2025)
32. Are Sites of Primary Lesions in Pemphigus Vulgaris More Prone to Relapse?, Oral Diseases (2024)
33. Comparison of Topical Nanocolloidal Silver Formulation Use With Eosin 2% Solution in Management of Hard-To-Heal Ulcers in Patients With Pemphigus Vulgaris, Journal of Wound Care (2020)
34. Alopecia Areata: A Review of Disease Pathogenesis, British Journal of Dermatology (2018)
35. Retrospective Study of Gingival Involvement in Pemphigus: A Difficult to Treat Phenomenon, Dermatologic Therapy (2022)
36. Genetic Predisposition to Ocular Surface Disorders and Opportunities for Gene-Based Therapies, Ocular Surface (2023)
37. Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged 70 Years and Older: A Systematic Review and Meta-Analysis, Transplantation and Cellular Therapy (2025)
38. Factors Associated With the Healing Time of Pemphigus Vulgaris Oral Lesions: A Prospective Study, Oral Diseases (2023)
39. Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2015)
40. Anti-Cd20 Antibody Treatment for B-Cell Malignancies, Resistance to Anti-CD20 Antibodies and approaches for their Reversal: Volume 2 (2023)
41. Rituximab As a Maintenance Treatment in Patients With Pemphigus Vulgaris: When Is the Right Time for Discontinuation?, Journal of Cosmetic Dermatology (2024)